Home > Farhad Hafezi, ESCRS 2020 – PACK-CXL Multicentre Trial (Part 2)
Corneal Disorders

Farhad Hafezi, ESCRS 2020 – PACK-CXL Multicentre Trial (Part 2)

Published Online: October 29th 2020

It was a pleasure to catch up with our Editorial Board member Prof. Farhad Hafezi (ELZA Institute, Zurich, Switzerland), the winner of the ESCRS 2020 Refractive Award! Here he discusses the PACK-CXL multicentre trial, and the benefits of this treatment.

Questions

  1. Which patients are likely to benefit most from photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL) treatment and in whom is it contraindicated? (00:06)
  2. How do you think that this treatment modality will translate into modern ophthalmology? (01:56)
  3. Do you think that PACK-CXL will replace antimicrobials in the future? (03:36)

Speaker Disclosures: Prof. Farhad Hafezi holds patents and applications fo corneal apparatus used for CXL, chromophore for CXL application; and is a shareholder and investor for EMAGine AG.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of ESCRS 2020.

Share this Video
Related Videos In Corneal Disorders
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar